CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target

We have read with great interest the case report by Hill et al. which reported favorable response of a patient with posttransplant lymphoproliferative disease (PTLD) treated with the anti-CD30 antibody brentuximab vedotin [1]. PTLD presents a major cause of mortality and morbidity after solid organ transplant in children. Most cases are Epstein – Barr virus (EBV)-associated. Traditionally, therapy includes reduction of immunosuppressive treatment as tolerated, control of EBV replication and cytotoxic chemotherapy. Treatment has been successfully improved with the

[1]  R. Tubbs,et al.  Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin , 2015, Leukemia & lymphoma.

[2]  Baoan Chen,et al.  Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma , 2015, Drug design, development and therapy.

[3]  R. Advani,et al.  Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. , 2014, Blood.

[4]  J. Lynch,et al.  Low‐Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children's Oncology Group Report , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Advani,et al.  Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. , 2012 .

[8]  G. Salles,et al.  Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. , 2012, The Lancet. Oncology.

[9]  E. Podack,et al.  CD30: an important new target in hematologic malignancies , 2011, Leukemia & lymphoma.

[10]  D. Crawford,et al.  Soluble CD30: A serum marker for Epstein–Barr virus‐associated lymphoproliferative diseases , 2011, Journal of medical virology.

[11]  C. Klein,et al.  CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Yamada,et al.  [Low-dose chemotherapy]. , 1996, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[13]  M. Lipinski,et al.  Isolation of a normal B cell subset with a Burkitt‐like phenotype and transformation in vitro with Epstein‐Barr virus , 1988, International journal of cancer.

[14]  G. Reibnegger,et al.  Neopterin and Endogenous Interferon Gamma in Serum of Patients with Epstein-Barr Virus-associated Lymphoproliferative Diseases , 1990 .